How much revenue does Venus Remedies make?

Venus Remedies reported 6.48 billion INR in revenue for fiscal year 2025, up 7.7% from 6.01 billion INR in fiscal year 2024. In Q3 2026 revenue was 1.80 billion INR.

What companies are similar to Venus Remedies?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Gufic Biosciences Limited (GUFICBIO.NS), Unichem Laboratories Limited (UNICHEMLAB.NS), Syncom Formulations (India) Limited (SYNCOMF.NS), Panacea Biotec Limited (PANACEABIO.NS).

Venus Remedies Limited (VENUSREM.NS) Stock

About Venus Remedies Limited

Venus Remedies Limited engages in the pharmaceutical business in India, Latin America, Europe, the Middle East, Africa, Asia, and internationally. The company is involved in the research and development of solutions focusing on antimicrobial resistance, oncology, skin and wound care, and pain management. It also provides analgesic, analgesic and antipyretic, antibiotic, antidiabetic anticoagulant,...

At a glance

Venus Remedies reported revenue of 6.48 billion INR for fiscal year 2025, up 7.7% from fiscal year 2024, and net income of 453.20 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 1.80 billion INR, up 1.9% from a year before.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.